Evaluating the anti-inflammatory and analgesic properties of maropitant: A systematic review and meta-analysis

Kinobe, Robert T.; Miyake, Yutaka

doi:10.1016/j.tvjl.2020.105471

Cited by 10 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Kinobe and Miyake [ 42 ] reported that maropitant reduces the minimum alveolar concentration of inhaled anesthetics, but without analgesic and anti-inflammatory activity, their systematic review and meta-analysis highlights the limited number of studies, requiring more targeted research to prove whether maropitant has such effects. IV infusions of drugs during elective surgical procedures aim at an antinociceptive effect, as there is no previous pain [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

Antinociceptive and analgesic effect of continuous intravenous infusion of maropitant, lidocaine and ketamine alone or in combination in cats undergoing ovariohysterectomy

et al. 2021

View full text Add to dashboard Cite

Background Multimodal analgesia consists of the combination of analgesic drugs at low doses to act in different places along the path of pain. Studies with continuous infusion of analgesic drugs in cats are not common. This study aimed to evaluate the analgesic effect of maropitant, lidocaine and ketamine alone or in combination (intravenous bolus + subsequent continuous intravenous infusion) in the management of acute postoperative pain in cats undergoing ovariohysterectomy. Seventy healthy cats undergoing an ovariohysterectomy received a standard anesthetic protocol consisting of acepromazine and morphine, propofol (anesthesia induction), and isoflurane (anesthesia maintenance). The animals were stratified into seven groups (n = 10 in each group): control (CG), maropitant (MG), lidocaine (LG), ketamine (KG), maropitant + lidocaine (LMG), maropitant + ketamine (KMG), and maropitant + lidocaine + ketamine (LKMG). All drugs were injected first as an intravenous bolus and then by continuous intravenous infusion. During surgery, esophageal temperature, respiratory rate, heart rate, oxygen saturation, expired isoflurane concentration, and partial pressure of carbon dioxide at the end of expiration were evaluated at 7 time points. Postoperative pain was evaluated for 6 h after extubation using the visual analogue scale and the UNESP-Botucatu multidimensional composite pain scale for assessing postoperative pain in cats. Results Adverse effects related to maropitant, lidocaine and ketamine infusion were not observed. Pain scores were lower in the MG, KG and LG groups when compared to the CG group using both scales. Although pain scores were also lower in all combination groups than CG, more animals in these groups required rescue analgesia compared to MG. This indicates that the postoperative analgesic effect of all drugs, either alone or in combination, confers analgesia, although the combinations did not promote greater analgesia. Conclusions Continuous intravenous infusion of maropitant, lidocaine, and ketamine alone induces postoperative analgesic effect in cats undergoing ovariohysterectomy, but combinations of these drugs did not increase the analgesic effect. No adverse effect was observed with any drug or their combination.

show abstract

Section: Discussionmentioning

confidence: 99%

Antinociceptive and analgesic effect of continuous intravenous infusion of maropitant, lidocaine and ketamine alone or in combination in cats undergoing ovariohysterectomy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Adequate analgesia can usually be provided by opioids and the benefits of providing analgesia outweigh the possible contribution of opioid use to gastric stasis. While maropitant has been suggested as an adjunctive analgesic, care should be taken before prescribing specifically for these purposes (Kinobe and Miyake 2020). Additional analgesics are rarely required in purely gastrointestinal conditions, but might reduce opioid requirements, and would include lidocaine and ketamine.…”

Section: General Approach To Gastrointestinal Intoxicationmentioning

confidence: 99%

Supporting the intoxicated patient: toxicants affecting the gastrointestinal and hepatobiliary systems

Cook¹,

Greensmith²

2020

In Practice

View full text Add to dashboard Cite

Background: The gastrointestinal and hepatic systems are the first to encounter many potentially toxic substances. Recognition, stabilisation and treatment of the consequences of intoxication are key to successful management.Aim of the article: This is the final article in a series of four. It focuses on toxicants that affect the gastrointestinal or hepatobiliary systems, outlining the aetiology of the clinical signs observed, along with diagnostic assessment and treatment considerations.

show abstract

“…The NK‐1 receptor antagonists are the standard of care in human cancer patients to prevent emesis associated with chemotherapy, and maropitant citrate is commonly administered clinically at 1 mg/kg intravenously (IV) or subcutaneously (SC) once daily for a broad range of emetic stimuli in dogs and cats (Benchaoui et al, 2007; De la Puente‐Redondo et al, 2007; Hickman et al, 2008; Kraus, 2013; Martin‐Flores et al, 2016; Ramsey et al, 2008; Rau et al, 2010; Trepanier, 2015; Vail et al, 2007). Maropitant citrate has also been investigated for anti‐inflammatory, analgesic, and inhalant anesthesia sparing effects, related to the involvement of substance P in several other physiologic pathways (Boscan et al, 2011; Kinobe & Miyake, 2020; Niyom et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration

Mones

Petritz

Knych

et al. 2022

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Maropitant citrate is a synthetic neurokinin‐1 receptor antagonist and substance P inhibitor used for control of emesis in dogs in cats. Maropitant citrate is used empirically in birds, despite a lack of pharmacokinetic data in avian species. The objective of this study was to determine the pharmacokinetic profile of a single dose of maropitant citrate 1 and 2 mg/kg subcutaneously (SC) in eight Rhode Island Red hens (Gallus gallus domesticus). A crossover study design was used with 1‐week washout between trials. Blood samples were collected over 36 h after drug administration. Plasma concentrations were measured using liquid chromatography–tandem mass spectrometry and pharmacokinetic parameters were determined via non‐compartmental analysis. The mean maximum plasma concentration, time to maximum concentration, and elimination half‐life following 1 and 2 mg/kg SC were 915.6 ± 312.8 ng/ml and 1195.2 ± 320.2 ng/ml, 0.49 ± 0.21 h and 1.6 ± 2.6 h, and 8.47 ± 2.24 h and 8.58 ± 2.6 h, respectively. Pharmacokinetic data suggests doses of 1 or 2 mg/kg SC may be administered every 12–24 h to maintain above target plasma concentration similar to dogs (90 ng/ml). These data provide a basis for further investigation of maropitant citrate pharmacokinetics and pharmacodynamics in birds.

show abstract

Evaluating the anti-inflammatory and analgesic properties of maropitant: A systematic review and meta-analysis

Cited by 10 publications

References 39 publications

Antinociceptive and analgesic effect of continuous intravenous infusion of maropitant, lidocaine and ketamine alone or in combination in cats undergoing ovariohysterectomy

Antinociceptive and analgesic effect of continuous intravenous infusion of maropitant, lidocaine and ketamine alone or in combination in cats undergoing ovariohysterectomy

Supporting the intoxicated patient: toxicants affecting the gastrointestinal and hepatobiliary systems

Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration

Contact Info

Product

Resources

About